Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Parabilis MedicinesPBLS -4.66%10 Market Cap is $3,852.84 Mil as of Jul. 25, 2026. GuruFocus rates PBLS with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 1,423 Biotechnology companies, Parabilis Medicines ranks better than 93.25% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Parabilis Medicines's share price for the quarter that ended in Dec. 2025 was $0. Parabilis Medicines's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 118.15 Mil. Therefore, Parabilis Medicines's market cap for the quarter that ended in Dec. 2025 was $0.00 Mil.
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Parabilis Medicines's Enterprise Value for Today is $4,364.58 Mil.
Parabilis Medicines (NAS:PBLS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Parabilis Medicines Market Cap Related Terms
Parabilis Medicines Market Cap Historical Data
* Premium members only.
The historical data trend for Parabilis Medicines's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parabilis Medicines Market Cap Chart
Parabilis Medicines Annual Data
Trend
Dec24
Dec25
Market Cap
0.00
0.00
Parabilis Medicines Semi-Annual Data
Dec24
Dec25
Market Cap
0.00
0.00
PBLS vs IDYA, ELVN, BEAM: Market Cap Comparison
For the Biotechnology subindustry, Parabilis Medicines's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Parabilis Medicines Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Parabilis Medicines's Market Cap distribution charts can be found below:
* The bar in red indicates where Parabilis Medicines's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Parabilis Medicines's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parabilis Medicines (PBLS) has a Market Cap of $3,852.84 Mil as of Jul. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Parabilis Medicines and its competitors. According to the industry distribution chart, Parabilis Medicines ranks #96 out of 1423 companies in the Biotechnology industry, placing it in the top 6.7%.
Is Parabilis Medicines' Market Cap too high?
Parabilis Medicines' current Market Cap is $3,852.84 Mil. The Biotechnology industry median Market Cap is 112.84. Parabilis Medicines' value of $3,852.84 Mil is 3314.3% above this industry median. Based on the distribution chart, Parabilis Medicines ranks #96 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Parabilis Medicines has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Parabilis Medicines' Market Cap compare to IDYA and ELVN?
According to the Biotechnology industry distribution chart, Parabilis Medicines ranks #96 out of 1423 companies for Market Cap. This places Parabilis Medicines in the top 7% of its industry — outperforming the majority of peers. The industry median Market Cap is 112.84. Parabilis Medicines' value of $3,852.84 Mil is 3314.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.84, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Parabilis Medicines's current Market Cap of $3,852.84 Mil is 3314.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Parabilis Medicines and its competitors. For the Biotechnology industry, the median Market Cap is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Parabilis Medicines's current Market Cap is $3,852.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parabilis Medicines stock overvalued right now?
Parabilis Medicines (PBLS) has a current Market Cap of $3,852.84 Mil. The current Market Cap is $3,852.84 Mil and 3314.3% above the Biotechnology industry median of 112.84. Parabilis Medicines' overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Parabilis Medicines (PBLS), the current Market Cap is $3,852.84 Mil as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ?-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/?-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
10GF Score
Get the complete analysis for PBLS
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBLS has been successfully added to your 
